Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.

Trial Profile

Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2014

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Chronic heart failure; Decompensated heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms REVIVE II study
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 26 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top